Ian Mortimer

New Capabilities

As of September 2026: Leading the company through the NDA submission and psychiatry trial pause

Xenon Pharmaceuticals stopped enrolling new patients in its Phase 3 depression and bipolar disorder trials on September 17 after participants reported neuropsychiatric side effects, including a small number of psychosis cases. The company's stock fell more than 25% the next day.

Updated Sep 18